Jeff Johnston, Amanda Stewart, Anita Berry and Lauren Lange represented 64 clients in Q3. The Hillsborough County Sheriff’s ...

Fintel reports that on November 28, 2025, HC Wainwright & Co. reiterated coverage of Travere Therapeutics (NasdaqGM:TVTX) ...

Renalys Pharma reports positive results from phase III study of sparsentan in Japanese patients with IgA nephropathy: Tokyo, Japan Friday, November 28, 2025, 13:00 Hrs [IST] Renal ...

Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.

Travere Therapeutics stock has doubled, and then some, in 2025 even as competition heats up for its bread-and-butter drug, ...

Anti-APRIL antibody Voyxact (sibeprenlimab) has been approved by the US regulator to reduce proteinuria in adults with ...

Travere Therapeutics' market cap has more than doubled in six months, reflecting confidence in FILSPARI's role in treating ...

In a Phase 3 clinical study evaluating the efficacy and safety of sparsentan in Japanese patients with IgA nephropathy (N=35), the percent change from baseline in the 24-hour urine ...

Today, members of the kidney community-including patients, policymakers, advocates, health care professionals, industry representatives and innovators-will gather for the American Kidney Fund (AKF)’s ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Travere Therapeutics Inc. has reached a new 52-week high, with its stock price climbing to 36.81 USD. This milestone reflects a significant upward trend for the company, which has experienced a ...